Sickle Cell Treatment Reauthorization Act of 2014 introduced in the House of Representatives

Captial in Washington DC

The Sickle Cell Treatment Reauthorization Act of 2014 introduced in the House of Representatives on July 16, 2014 by Congressman Danny K. Davis (D-IL) and Michael C. Burgess (R-TX). The purpose of this Bill (H.R. 5124) is to amend the Public Health Service Act to reauthorize a Sickle Cell Disease Prevention and Treatment Demonstration Program and to provide for Sickle Cell Disease Research, Surveillance, Prevention, and Treatment.

The priority of the Sickle Cell Treatment Reauthorization, H.R. 5124 is to improve quality of life, treatment, and prevention for those affected by Sickle Cell Disease. Among numerous modified benefits of the Bill includes conducting or supporting research to expand the understanding of the cause of, and to find a cure for, Sickle Cell Disease. It will expand, coordinate, and implement transition services for adolescences with SCD making the transition to adult care. It also aims to establish funding to conduct surveillance and maintain data on the prevalence and distribution of SCD and its associated health outcomes, complications, and treatments; conduct public health initiatives with respect to SCD including education and training for patients, communities, and health care providers; increased efforts to improve access to and receipt of high-quality SCD related healthcare; and to identify and evaluate promising strategies for prevention. The Bill is designed to provide grant funding for up to twenty-five (25) Sickle Cell Treatment Centers throughout the United States for each fiscal year from 2015 through 2020.

Congressman Danny K. Davis (D-IL) and Congressman Michael C. Burgess (R-TX)

Photo (L-R): Congressman Danny K. Davis and Congressman Michael C. Burgess

The K.I.S. Foundation, Inc. applauds the efforts of Congressman Davis and Congressman Burgess in joining the fight in helping to raising public awareness and calling for change. KiKi Shepard, Founder & Executive Director of The K.I.S. Foundation, Inc. states, “we are happy to educate all our champions of support about the Sickle Cell Treatment Reauthorization Act of 2014. The SCTRA is bipartisan legislation to renew the nation’s programs for research, surveillance, prevention, and treatment of SCD for another five(5) years, is a huge step for maintained, comprehensive care for the Sickle Cell Disease community.”

Representatives Danny K. Davis and Michael C. Burgess development of this Bill was only the first step. It will now need to be introduced to the United States Senate for H.R. 5124 to get passed.

Tags: , , , , , , , , , , , , , ,